Marra Kyle V, Wagley Sushant, Omar Ahmed, Kinoshita Taiga, Kovacs Kyle D, Silva Paolo, Kuperwaser Mark C, Arroyo Jorge G
*Retina Service, Division of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; †University of California, San Diego School of Medicine, San Diego, California; ‡College of Human Medicine, Michigan State University, East Lansing, Michigan; §Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts; ¶Department of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, Egypt; and **Albert Einstein College of Medicine, New York, New York.
Retina. 2015 Jun;35(6):1072-83. doi: 10.1097/IAE.0000000000000449.
To evaluate the efficacy of combination pars plana vitrectomy, endoscopic peripheral panretinal photocoagulation, and endocyclophotocoagulation (ECP) as compared with standard care in patients with neovascular glaucoma.
This age-matched case-controlled retrospective series of 54 eyes compared the clinical outcomes between a consecutive series of combination pars plana vitrectomy/panretinal photocoagulation/ECP (n = 27) versus the current standard of care (n = 27) for patients with neovascular glaucoma. "Standard" treatments for patients with neovascular glaucoma include panretinal photocoagulation, intravitreal bevacizumab, filtration surgery, pars plana vitrectomy, and Ahmed valve placement.
After 1 year, mean intraocular pressure reduced from 40.7 ± 12.40 mmHg preoperatively to 12.3 ± 4.84 mmHg (P < 0.001) in the ECP group and from 34.7 ± 12.38 mmHg to 23.2 ± 12.34 mmHg in the control group (P = 0.002). Compared with controls, the mean drop in intraocular pressure in the ECP group was significantly greater at all postoperative visits. Logarithm of the minimal angle of resolution visual acuity outcomes were similar in both groups. There were 2 cases (7.4%) of postoperative phthisis bulbi in each group.
Endoscopic pars plana vitrectomy, panretinal photocoagulation, and ECP seem to control intraocular pressure to a greater extent than standard glaucoma treatments in patients with neovascular glaucoma. In this aged-matched comparative case series, there was no significant difference between the two treatments' effects on visual acuity.
评估玻璃体切割联合内镜下全视网膜光凝及睫状体光凝术(ECP)与标准治疗方法相比,对新生血管性青光眼患者的疗效。
本年龄匹配的病例对照回顾性系列研究纳入了54只眼,比较了连续性系列玻璃体切割联合全视网膜光凝及ECP治疗组(n = 27)与新生血管性青光眼患者当前标准治疗组(n = 27)的临床结局。新生血管性青光眼患者的“标准”治疗方法包括全视网膜光凝、玻璃体腔内注射贝伐单抗、滤过手术、玻璃体切割术和Ahmed人工瓣膜植入术。
1年后,ECP组平均眼压从术前的40.7±12.40 mmHg降至12.3±4.84 mmHg(P < 0.001),对照组从34.7±12.38 mmHg降至23.2±12.34 mmHg(P = 0.002)。与对照组相比,ECP组在所有术后随访时眼压的平均降幅均显著更大。两组最小分辨角对数视力结果相似。每组均有2例(7.4%)术后眼球痨。
在新生血管性青光眼患者中,内镜下玻璃体切割、全视网膜光凝及ECP似乎比标准青光眼治疗方法能更好地控制眼压。在这个年龄匹配的对比病例系列中,两种治疗方法对视力的影响无显著差异。